Psychiatric and neurodegenerative diseases cause several billion euros of costs worldwide annually. Often, many neuro-psychiatric patients suffer from synaptic connectivity damage and its dispersion inside the brain. Within the project “synProfiler”, the company Systasy Bioscience GmbH strives for a measurement system to directly quantify the number of stimulating or inhibiting synapses. The system shall be used in human cellular disease models. In the future, pharmacological agents should be tested fast and efficiently concerning their competences for accurate synapses’ modulation.
